Title : Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study.

Pub. Date : 2020 Apr

PMID : 32065359






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: After the 8-week treatment, percentage change (least-square means +- standard error) in the apoB/A1 ratio in the rosuvastatin/ezetimibe group was significantly decreased compared to the rosuvastatin group (- 46.14 +- 1.58% vs. - 41.30 +- 1.58%, respectively; P = 0.03). Rosuvastatin Calcium apolipoprotein B Homo sapiens
2 The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group. Rosuvastatin Calcium apolipoprotein B Homo sapiens
3 The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group. Rosuvastatin Calcium apolipoprotein B Homo sapiens
4 CONCLUSION: The apoB/A1 ratio was significantly reduced in patients receiving combination therapy with ezetimibe and rosuvastatin compared to those receiving rosuvastatin monotherapy. Rosuvastatin Calcium apolipoprotein B Homo sapiens
5 CONCLUSION: The apoB/A1 ratio was significantly reduced in patients receiving combination therapy with ezetimibe and rosuvastatin compared to those receiving rosuvastatin monotherapy. Rosuvastatin Calcium apolipoprotein B Homo sapiens